---
title: "J&J Jumps as UBS Lifts Its Target to $320"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297812991.md"
description: "Johnson & Johnson shares rose 1.2% to $274.395 after UBS raised its price target from $280 to $320, maintaining a Buy rating. UBS cited strong Q2 sales growth of 6.6% and raised 2026 sales guidance. Despite the upgrade, J&J trades significantly above its intrinsic value, requiring successful clinical and regulatory outcomes to justify further gains."
datetime: "2026-09-02T16:42:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297812991.md)
  - [en](https://longbridge.com/en/news/297812991.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297812991.md)
generator: "portal-rs"
---

# J&J Jumps as UBS Lifts Its Target to $320

Johnson & Johnson , the pharmaceutical and medical-technology powerhouse, surged roughly 1.2% to $274.395 Wednesday after UBS cranked its price target from $280 to $320. Barron's reported that J&J became the Dow's biggest point booster in early trading. Wall Street heard the message loud and clear: UBS sees more fuel in this rally.

The firm kept its Buy rating, pointing to faster growth and more value hiding inside J&J's pharmaceutical pipeline. The operating engine is already delivering. J&J's second-quarter results showed sales climbing 6.6% to $25.3 billion, while management raised its 2026 sales midpoint to $101.1 billion and adjusted earnings guidance to $11.68 per share.

But the valuation is flashing yellow. The picture shows J&J trading 42.25% above its $192.90 GF Value, leaving little room for pipeline stumbles. UBS's $320 target still points to roughly 16.6% upside from $274.395, but J&J must earn every dollar. Clinical wins, regulatory approvals and successful launches now matter more than another round of multiple expansion.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)

## Related News & Research

- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?](https://longbridge.com/en/news/298140186.md)
- [4,000 Shares in Ligand Pharmaceuticals Incorporated $LGND Acquired by JW Asset Management LLC](https://longbridge.com/en/news/298374596.md)
- [ANI Pharmaceuticals (ANIP), Why Is Fresh Attention Building Around It?](https://longbridge.com/en/news/298119801.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**